Currently there are no interventional, drug or gene therapy trials that are available for MAPT patients, regardless of symptom status. Any type of intervention that patients receive is for symptom management. However, because the main protein causing the tangles in the neurons is Tau, the good news is there are drugs currently in trial for the Tau tangles that occur with Alzheimer’s Disease. These are potentially promising for the MAPT families, pending their success with Alzheimer's Disease. IONIS- MAPT Rx is the current interventional trial that could show some promise. It's critical that MAPT families participate in any promising trial, while we organize to create our own through fundraising and advocacy efforts. Below are some worth watching and/or participating in.

BEYONDD:

Biomarker Evaluation in Young Onset Dementia from Diverse Populations

PET Tracer:

APN-1607, Aprinoia Therapeutics

Biogen ASO Trial

Aprinoia Therapeutics

Sodium Selenate Trail in New Zealand & Australia

Anti-Microtubule Trial from Eisai

Amisulpride as a potential disease-modifying drug in the treatment of tauopathies

Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity

Gamma-Induction in FTD (GIFTeD)

GENFI

Genes, Brains and Decisions

Development in Families with Neurodegenerative Disease

ALLFTD